JPRN-jRCT2080222332已完成1 期
A Phase 1 Study of LY2835219 in Japanese Patients with Advanced Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have histological or cytological evidence of a diagnosis of cancer (either a solid tumor or a lymphoma) that is advanced and/or metastatic
- •- Must be, in the judgment of the investigator, an appropriate candidate for the experimental therapy after available standard therapies have failed to provide clinical benefit for their disease
- •- Have the presence of measurable or non-measurable disease as defined by the Response Evaluation Criteria in Solid Tumors Guideline Version 1.1, or the Revised Response Criteria for Malignant Lymphoma Guideline
- •- Have adequate organ function
- •- Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, immunotherapy, and investigational therapy, for at least 21 days before the first dose of study drug and recovered from the acute effects of any such therapy
- •- Males must agree to use medically approved barrier contraceptive precautions during the study and for 3 months following the last dose of study drug
- •- Females with child bearing potential: must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test equal to or less than 7 days before the first dose of study drug.
- •- A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, the female must stop breastfeeding from the day of the first study drug administration until at least 3 months after the last administration
- •- Have an estimated life expectancy of equal to or more than 12 weeks
- •- Are able to swallow capsules
排除标准
- 未提供
研究者
相似试验
未知
1 期
A Phase 1 Study of LY2875358 in Japanese Patients With Advanced MalignanciesSolid Tumors, LymphomaJPRN-jRCT2080221810Eli Lilly Japan K.K.
未知
1 期
A Phase 1 Study of LY2940680 in Japanese Patients with Advanced Solid Tumorseoplasm MetastasisJPRN-jRCT2080222179Eli Lilly Japan K.K.
未知
1 期
A Phase 1 Study of LY2584702 in Japanese Patients with Solid TumorsCancerJPRN-jRCT2080221292Eli Lilly Japan K.K.
已完成
1 期
A Phase 1 Study of LY3039478 in Japanese Patients with Advanced Solid Tumors I6F-JE-JJCCAdvanced Solid TumorJPRN-jRCT2080223309Eli Lilly Japan K.K.
未知
1 期
A Phase 1 Study of LY2606368 in Japanese Patients with Advanced Solid TumorseoplasmJPRN-jRCT2080222962Eli Lilly Japan K.K.